Also considered
12 papers judged, 3 emailed · Read the digest →
Narrative review in JCO on optimizing neoadjuvant/postneoadjuvant therapy for HER2+ early breast cancer, including de-escalation strategies and new agents like trastuzumab deruxtecan. Offers a practical framework for risk-adapted, biomarker-guided treatment selection in this setting.
Phase 3 randomized equivalence trial comparing a pertuzumab biosimilar to reference pertuzumab in neoadjuvant HER2-positive breast cancer, published in Clinical Cancer Research. Demonstrates biosimilarity in pathologic response, safety, and pharmacokinetics, supporting the biosimilar as an interchangeable treatment option.
Phase 3 randomized trial in HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, published in JCO. A novel HER2-directed antibody-drug conjugate improved progression-free survival over trastuzumab emtansine, supporting it as a potential new standard second-line option.
Meta-epidemiologic analysis of randomized trials of antibody-drug conjugates in metastatic breast cancer, published in JNCI. Finds that PFS effects consistently overstate OS effects, informing how oncologists interpret PFS-based ADC trial results and regulatory decisions.
Phase 1b study of the novel EGFR-HER3 bispecific antibody-drug conjugate iza-bren in heavily pretreated metastatic breast cancer (HER2+, HR+/HER2-, and triple-negative), published in Annals of Oncology. Shows clinically meaningful and durable objective responses across subtypes, signaling a promising new ADC option pending further trials.
Retrospective translational study in Clinical Cancer Research examining ERBB2 activating mutations as a predictor of response to trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer, with supporting preclinical mechanistic data. Suggests these mutations could help identify patients likely to benefit more from T-DXd.
Preclinical translational study (J Immunother Cancer) combining epigenetic and cytokine therapy with anti-PD-1 in checkpoint-resistant murine colorectal and breast cancer models, identifying an immune-niche gene signature associated with favorable clinical response to checkpoint blockade in patient genomic datasets. Suggests a rational combination strategy and biomarker to overcome anti-PD-1 resistance, though still early-stage evidence.
Randomized, placebo-controlled dose-finding trial (KARISMA) in healthy women examining endocrine biomarker changes across low-dose tamoxifen regimens, published in JNCI. Provides mechanistic support for lower-dose tamoxifen in breast cancer prevention but reports only surrogate endocrine markers, not cancer outcomes.
Descriptive analysis of FDA (neo)adjuvant drug approvals for solid tumors (2010-2023), published in JNCI, spanning melanoma, breast, and lung cancer trials. Highlights inconsistencies in trial design, endpoint reporting, and quality-of-life data that inform how oncologists interpret the evidence behind approved (neo)adjuvant regimens.
Retrospective cohort study in stage I triple-negative breast cancer published in European Journal of Cancer, evaluating a gene-expression assay and stromal TILs as prognostic biomarkers. Findings suggest potential to identify very-low-risk subsets, but the markers were not predictive of therapy response and did not significantly stratify recurrence risk overall.
Translational cohort study in JNCI examining polygenic risk scores and pathogenic variants for predicting subsequent breast cancer risk in childhood cancer survivors. Informs risk stratification and surveillance rather than therapy selection, so it refines screening discussions rather than treatment decisions.
Prospective ctDNA substudy of a phase 3 trial (NSABP B-59) in stage II/III triple-negative breast cancer treated with neoadjuvant chemotherapy with or without atezolizumab, published in JCO Precision Oncology. Shows ctDNA clearance after therapy correlates with distant recurrence risk, supporting its potential use as a prognostic tool in early TNBC.